HNRNPH2

Across TCGA pan-cancer cohorts, HNRNPH2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HNRNPH2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher HNRNPH2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HNRNPH2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where HNRNPH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.799	0.390	.004	32	view →
PDAC	OS	Median	All	0.365	0.592	.010	31	view →
CCRCC	OS	Median	All	1.000	0.674	.009	17	view →
OV	DFS	Median	All	0.858	1.000	.025	4	view →
GBM	DFS	Tertile	All	0.456	0.212	.006	4	view →
LSCC	OS	Median	All	0.800	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HNRNPH2–LUAD (OS)

Open the LUAD breakdown →